Chemotherapy News and Research

Latest Chemotherapy News and Research

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

$Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC$

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.

19 Jun 2015

Genes could help physicians make informed treatment decisions for metastatic colorectal cancer patients

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal cancer patients.

18 Jun 2015

New technique could allow scientists to pinpoint areas on enzymes that drive chemical reactions

Researchers from Cardiff University have pioneered a new technique that will enable scientists to precisely pinpoint the areas on an enzyme that help to speed up chemical reactions.

18 Jun 2015

ALK1 protein determines the extent of breast tumour's spread in the body

For breast cancer to be fatal, the tumour has to send out metastases to other parts of the body. The cancer cells are spread via the blood vessels, and a research team at Lund University in Sweden has now proven that the protein ALK1 determines the extent of the tumour's spread in the body.

17 Jun 2015

RPCI receives NCI grant to continue research program on photodynamic therapy for head and neck cancers

Roswell Park Cancer Institute has received continuation of a prestigious program project grant from the National Cancer Institute for research through the Roswell Park Photodynamic Therapy Center.

17 Jun 2015

CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

Ventana Medical Systems, Inc., a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL Marker Study (PALMS) in this month's issue of Cancer Cytopathology. The PALMS study, which enrolled more than 27,000 women from five European countries, was designed to evaluate the diagnostic performance of the CINtec PLUS Cytology test in detecting pre-cancerous cervical disease compared to HPV testing and more traditional screening methods like Pap cytology.

16 Jun 2015

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC).

16 Jun 2015

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Stony Brook University has entered into a licensing agreement with a startup company, CadheRx Therapeutics, to develop and market an anti-cancer technology discovered by Sabine Brouxhon, MD, Clinical Associate Professor in the Department of Emergency Medicine at Stony Brook University School of Medicine.

16 Jun 2015

DAPK1 protein may be a promising new therapeutic target for most aggressive breast cancers

Although traditionally understood to induce death in cancer cells, researchers at The University of Texas MD Anderson Cancer Center have discovered that the DAPK1 protein is actually essential for growth in breast and other cancers with mutations in the TP53 gene. This discovery indicates DAPK1 may be a promising new therapeutic target for many of the most aggressive cancers.

16 Jun 2015

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Ventana Medical Systems, Inc., a member of the Roche Group, today announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's FDA approved targeted therapy, XALKORI (crizotinib).

15 Jun 2015

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Mesothelioma.us, an educational and authoritative website that offers free and in-depth resources for mesothelioma patients and their families, has just released a new case study that focuses on the experimental treatments for the disease.

15 Jun 2015

Study explores role of ALK1 protein in breast cancer metastasis

Pietras said that although prognosis for breast cancer is relatively good when detected in its early stages, metastatic disease is the cause of 90 percent of all cancer-related deaths. Therefore, learning more about the metastatic process and finding new cures to inhibit disease spread is at the center of clinical attention.

15 Jun 2015

Researchers identify gene variant that makes breast cancer cells more aggressive

A particular human gene variant makes breast cancer cells more aggressive. Not only are these more resistant to chemotherapy but also leave the primary tumour and establish themselves in other parts of the body in the form of metastases. An international group of researchers led by Lukas Kenner of MedUni Vienna has now identified a gene, AF1q, as being substantially responsible for this and recognized it as a possible starting point for more accurate diagnosis and potential targeted therapeutic approaches.

15 Jun 2015

UIC study shows that brain cell density remains constant in normal aging

New, ultra-high-field magnetic resonance images (MRI) of the brain by researchers at the University of Illinois at Chicago provide the most detailed images to date to show that while the brain shrinks with age, brain cell density remains constant.

14 Jun 2015

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to evaluate scientifically targeted combination approaches with afatinib in the treatment of non-small cell lung cancer (NSCLC).

12 Jun 2015

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report today. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year.

12 Jun 2015

Daily dose of aspirin effective at blocking breast tumor growth

"Take two aspirin and call me in the morning" has been the punchline for countless jokes. Could it also be good advice for cancer patients? A lab study to appear in the July 2015 issue of Laboratory Investigation found that a daily dose of aspirin was effective at blocking breast tumor growth. Previous studies have already shown a similar effect on colon, gastrointestinal, prostate, and other cancers.

12 Jun 2015

Discovery may help scientists attack the root of deadliest brain tumors

Some brain tumors are notoriously difficult to treat. Whether surgically removed, zapped by radiation or infiltrated by chemotherapy drugs, they find a way to return. The ability of many brain tumors to regenerate can be traced to cancer stem cells that evade treatment and spur the growth of new tumor cells.

11 Jun 2015

New gene mutations in ADAMTS family may contribute to outcomes in ovarian cancer

There is the Addams Family. And then there is the ADAMTS family. While one is mindless entertainment, the latter may prove to be a new genetic avenue for designing ovarian cancer treatment.

11 Jun 2015

Chemotherapy News and Research

Latest Chemotherapy News and Research

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Genes could help physicians make informed treatment decisions for metastatic colorectal cancer patients

New technique could allow scientists to pinpoint areas on enzymes that drive chemical reactions

ALK1 protein determines the extent of breast tumour's spread in the body

RPCI receives NCI grant to continue research program on photodynamic therapy for head and neck cancers

CINtec PLUS Cytology test more effective than HC2 HPV test in identifying women with precancerous lesions

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

DAPK1 protein may be a promising new therapeutic target for most aggressive breast cancers

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Mesothelioma.us releases new case study that focuses on experimental treatments for mesothelioma

Study explores role of ALK1 protein in breast cancer metastasis

Researchers identify gene variant that makes breast cancer cells more aggressive

UIC study shows that brain cell density remains constant in normal aging

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Daily dose of aspirin effective at blocking breast tumor growth

Discovery may help scientists attack the root of deadliest brain tumors

New gene mutations in ADAMTS family may contribute to outcomes in ovarian cancer

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in